A group of over 100 institutional investors have written to Dutch medical technology company Philips demanding compensation of €800 million for “significant losses to shareholders” over the sleep ...

This is not the only recall the company is dealing with. Philips’ Respironics business has been facing issues with some of its sleep apnea products since June 2021 when it issued a recall of 15 ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

At least two deaths and over a hundred injuries have been linked to a malfunctioning heart monitoring device from Philips and its subsidiary, Braemer. The company affirmed in a statement that that the ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

Matthew Philips, an editor at CNN, replied, “Gonna hold you to that one cowboy!" That exchange, from November 2021, is among the ... including, if I recall, legal status, which didn’t seem ...

The latest Class I recall comes as Philips seeks to move beyond a significant ... its $2.8 billion acquisition of BioTelemetry in 2021.

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect cases of hidden, transient arrhythmias that may only last minutes at a time.